September 11th 2025
Oxford’s Prof Katrina Lythgoe and Mahan Ghafari, DPhil, report ONS-CIS data on 576 persistent UK infections with rapid within-host evolution and rare transmission after one month.
September 10th 2025
William Hanage, PhD, discusses viral evolution, transmission risk, and clinical implications for immunocompromised patients.
September 3rd 2025
Single-center randomized trial shows lower infection rates and extended time to SARS-CoV-2 infection, though larger studies are needed to confirm findings.
September 2nd 2025
Supported by phase 3 SCORPIO-PEP trial data, ensitrelvir could become the first oral therapy to prevent COVID-19 following exposure, with an FDA decision due June 16, 2026.
August 29th 2025
Spikevax and mNEXSPIKE authorized for older adults and high-risk individuals; experts emphasize protection against severe COVID-19 outcomes.
Could a Japanese Encephalitis Drug Prevent COVID-19?
March 19th 2020A drug known to inhibit a cellular protease TMPRSS2 could potentially be a novel therapeutic intervention for COVID-19 infections, according to German investigators who found that the cellular protein may allow entry of SARS-CoV-2 into lung cells.
Read More
COVID-19 Model Shows Travel Restrictions Work, But Testing and Isolation Key
March 16th 2020A mathematical model based on 4 publicly available data sets finds travel restrictions cut the rate of transmission in Wuhan, China. It also found that it likely takes several cases in a given location before the virus sparks an outbreak.
Read More
259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831